GSK 2315698

Drug Profile

GSK 2315698

Alternative Names: 2315698; CPHPC - GlaxoSmithKline; GSK2315698; GSK2315698A

Latest Information Update: 05 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pentraxin Therapeutics
  • Developer GlaxoSmithKline
  • Class Antidementias
  • Mechanism of Action Serum amyloid P component inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyloidosis

Most Recent Events

  • 10 Jul 2017 Phase-II clinical trials in Amyloidosis (Combination therapy) in United Kingdom (IV) (NCT03044353)
  • 05 Jun 2017 GlaxoSmithKline initiates a phase I trial in Amyloidosis in United Kingdom (SC, Injection) (EudraCT2016-003284-19)
  • 01 Dec 2016 GlaxoSmithKline completes a phase-I trial in Amyloidosis (In volunteers) in Japan (IV) (NCT02953808)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top